New Perspectives in Transporter Biology (FASEB Conference)

描述（由申请人提供）：本申请代表了一个会议的支持，将在美国实验生物学学会联合会（FASEB）的主持下举行的请求，题为“运输生物学的新视角”。 关于这个主题的第五届两年一度的FASEB会议定于2005年7月23日开始，7月28日结束，地点在佛蒙特州萨克顿河的佛蒙特学院。 这次会议的重点是转运蛋白，一大类膜蛋白是必不可少的各种现象，包括吸收和分配的营养物质，代谢产物的选择性肾排泄，分子的运动穿过血脑屏障，包装成囊泡的神经递质，和清除/终止突触释放的神经递质。 在过去的15年里，转运蛋白过程的研究的复杂性已经大大提高，因为克隆和随后的工具（抗体，表达系统等），可用于其研究的发展。 过去的一年半是运输生物学的分水岭。 现在有一些家庭成员的结构信息，这是在我们的药物代谢/人类多态性研究所带来的行动的基因组学的理解日益复杂，和新的技术/模型系统已经开发研究转运蛋白生物学。 这些转运蛋白的功能改变和/或突变与多种疾病有关，包括癫痫、头部创伤、肌萎缩侧索硬化症（ALS）、抑郁症、注意缺陷多动障碍（ADHD）、糖尿病、直立性低血压、胱氨酸尿症、囊性纤维化、HHH综合征等;“转运蛋白病”的名单越来越多。 尽管一些药物靶向这些转运蛋白（抗抑郁药，抗癫痫药，治疗ADHD的药物），但考虑到这类功能相关蛋白所代表的膜靶点的数量，这仍然是一个令人惊讶的小数量的药物。 这次会议汇集了使用结构，生物物理，分子，药物基因组学，生物化学，细胞生物学和生理学技术来研究这些蛋白质的个人。 此外，它汇集了对不同器官系统和疾病过程感兴趣的个人。 本次会议的首要目标是促进研究运输者的各个学科之间的交叉和合作。 这次会议的长期目标是培养个人财团，他们将以编程方式共同研究这类重要的膜蛋白。

DESCRIPTION (provided by applicant): This application represents a request for support of a conference that will be held under the auspices of the Federation of American Societies of Experimental Biology (FASEB), entitled "New Perspectives in Transporter Biology". The fifth bi-annual FASEB conference on this topic is scheduled to occur at Vermont Academy in Saxtons River, Vermont starting on July 23rd and ending on July 28th of 2005. This conference focuses on transporters, a large class of membrane proteins that are essential for diverse phenomena, including absorption and distribution of nutrients, selective renal excretion of metabolites, movement of molecules across the blood brain barrier, packaging of neurotransmitters into vesicles, and clearance/termination of synaptically released neurotransmitter. Over the last 15 years, the sophistication of studies of transporter processes has dramatically improved because of the cloning and subsequent development of tools (antibodies, expression systems, etc) that can be used for their study. The past year and half have been a watershed in transporter biology. There is now structural information on a few members of the family, this is increasing sophistication in our understanding of the genomics of drug metabolism/action brought about by studies of human polymorphisms, and new techniques/model systems have been developed to study transporter biology. Altered function and/or mutations in these transporters have been implicated in diverse diseases, including epilepsy, head trauma, amyotrophic lateral sclerosis (ALS), depression, attention deficit hyperactivity disorder (ADHD), diabetes, orthostatic hypotension, cystinuria, cystic fibrosis, HHH syndrome, etc; there is a growing list of 'transporteropathies'. Although some drugs target these transporters (anti-depressants, antiseizure, drugs to treat ADHD), this is still a surprisingly small number of drugs considering the number of membrane targets represented by this class of functionally related proteins. This meeting brings together individuals who use structural, biophysical, molecular, pharmacogenomic, biochemical, cell biological, and physiological techniques to study these proteins. Furthermore, it brings together individuals who have interests in diverse organ systems and disease processes. An over-riding goal of this meeting is to facilitate cross-fertilization and collaboration between the various disciplines that study transporters. The long-term goal of this meeting is to cultivate consortiums of individuals who will work together programmatically to study this important class of membrane proteins.